Drug Trial Radar · NCT07778667
A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Feb 13, 2029
Study completion Mar 15, 2029
Sponsor
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to learn how well lucerastat works and how safe it is in untreated adult male participants with Fabry disease. The main question this clinical trial aims to answer is: • Does treatment with lucerastat affects the amount of globotriaosylceramide (Gb3), a fatty substance that builds up in the kidneys, in untreated adult men with Fabry disease? This is an open-label, single-arm trial, which means that participants will know which trial medication they receive and only one trial medication will be given. Trial participants will: * Take lucerastat every day for 18 months * Have kidney biopsies at the end and start of the trial * Visit the clinic 10 times for check-up and tests * Take part in the trial for up to 21 months in total
Conditions
- Fabry Disease
Interventions
LucerastatDrug
Hard gelatine capsules of 250 mg lucerastat
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline to Month 18 in kidney Gb3 BLISS score (average number of Gb3 inclusions per kidney peritubular capillary (PTC)).Time frame: Baseline and Month 18
Locations
16 sites in 5 countries. Site status is shown where the registry gives one.
University of Alabama of Birmingham
Birmingham, Alabama · Not yet recruiting
UCSF Benioff Childens Hospital
Oakland, California · Not yet recruiting
UF Health Center for Pediatric Neuromuscular and Rare Diseases
Gainesville, Florida · Not yet recruiting
Emory University School of Medicine
Atlanta, Georgia · Not yet recruiting
Ann & Robert H. Lurie Childrens Hospital of Chicago
Chicago, Illinois · Not yet recruiting
The University of Minnesota, Fairview Health
Minneapolis, Minnesota · Not yet recruiting
Hospital of University Pennsylvania, Translational Medicine and Human Genetics
Philadelphia, Pennsylvania · Not yet recruiting
Dallas Nephrology Associates (DNA) - Dallas Landry Office Practice
Dallas, Texas · Recruiting
VG Site pharmacy Dept 6 N-279
Halifax, Nova Scotia, Canada · Not yet recruiting
CIUSSS-NIM/Hopital du sacre-Coeur de MontrealUnite de Recherche, Local C2030
Montreal, Quebec, Canada · Not yet recruiting
Hôpital Raymond-Poincaré
Garches, Île-de-France Region, France · Not yet recruiting
Centre Hospitalier Universitaire de Toulouse -Hôpital Purpan
Toulouse, Midi-Pyrénées, France · Not yet recruiting
Universitaetsklinikum Wuerzburg AöR
Grombuehl, Bavaria, Germany · Not yet recruiting
Charite Universitaetsmedizin Berlin KöR
Mitte, State of Berlin, Germany · Not yet recruiting
The Royal Free London NHS Foundation Trust - The Royal Free
London, City of London, United Kingdom · Not yet recruiting
Salford Royal NHS Foundation Trust part of the Northern Care
Salford, Lancashire, United Kingdom · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.